« Back to Record
Citation APA

Tannock, I. I., Fizazi, K., Ivanov, S., Karlsson, C. T., Fléchon, A., Skoneczna, I., Orlandi, F., Gravis, G., Matveev, V., Bavbek, S., Gil, T., Viana, L., Arén, O., Karyakin, O., Elliott, T., Birtle, A., Magherini, E., Hatteville, L., Petrylak, D., Tombal, B., & Rosenthal, M. (2013). Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial. Lancet oncology, 14(8), 760-768. doi:10.1016/S1470-2045(13)70184-0


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/184098

Tannock, I. I., Fizazi, K., Ivanov, S., Karlsson, C. T., Fléchon, A., Skoneczna, I., Orlandi, F., Gravis, G., Matveev, V., Bavbek, S., Gil, T., Viana, L., Arén, O., Karyakin, O., Elliott, T., Birtle, A., Magherini, E., Hatteville, L., Petrylak, D., Tombal, B., & Rosenthal, M. (2013). Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial. Lancet oncology, 14(8), 760-768. doi:10.1016/S1470-2045(13)70184-0